This version substantially revises and extends Version 1.0. The primary hypothesis has been reformulated within a protein corona framework: PS80 is now presented as an efficiency amplifier of a baseline apolipoprotein adsorption mechanism (H0) rather than a prerequisite, broadening the scope of the hypothesis to all aluminum-adjuvanted vaccines. The title has been updated accordingly. New material includes: A dedicated introduction to protein corona dynamics and kinetic competition in Section 2. A two-level hypothesis structure (H1 primary + H0 corollary) in Section 5, with an additional falsifiable prediction (H0a). A new subsection 7.2 on organ-specific distribution via LDLR expression and its relationship to autoimmune disease patterns, including ASIA syndrome (Shoenfeld (2) Gherardi et al. demonstratedthat vaccine aluminum particles exhibit long-term biopersistence and can translocate to the brain via intracellularphagocyte-mediated transport; (3) Mold, Umar, King and Exley (2018) reported extraordinary aluminumconcentrations in post-mortem brain tissue from donors with autism spectrum disorder, with aluminum foundpredominantly in microglia-like and non-neuronal inflammatory cells. Implications: If confirmed, this mechanism would represent an additional pathway for aluminum adjuvantneurodeposition. The protein corona framework further explains interindividual variability in neurological adverseevent profiles. A structurally analogous parallel hypothesis is articulated regarding PEGylated lipid nanoparticles inmRNA vaccines. Both hypotheses are falsifiable and amenable to direct experimental testing
Añaños et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: